Navigation Links
Controversial Cholesterol Drug Might Lower Blood Sugar Levels in Diabetics
Date:7/19/2011

By Serena Gordon
HealthDay Reporter

MONDAY, July 18 (HealthDay News) -- Australian researchers have discovered that a drug initially designed to raise levels of "good" HDL cholesterol has an unexpected benefit in people with type 2 diabetes: it lowered their blood sugar.

That's the good news.

The bad news is that this particular medication, torcetrapib, also has a significantly increased risk of cardiovascular problems and mortality. In fact, the problems were so significant with torcetrapib that the initial trial, known as ILLUMINATE, was halted early. However, there are two other medications -- dalcetrapib and anacetrapib -- in the same drug class as torcetrapib that don't appear to have the same heart risks, according to the study authors.

What remains to be seen is if these other drugs have the same benefits that torcetrapib did.

"Diabetic patients in the ILLUMINATE trial who received the combination of atorvastatin plus torcetrapib had lower levels of [short-term and long-term blood sugar] than those receiving atorvastatin alone, indicating that treatment with torcetrapib, compared with placebo, resulted in improvement in diabetic control," wrote the Australian researchers.

Atorvastatin, better known by its brand name, Lipitor, is a statin that's commonly prescribed to reduce levels of LDL, or "bad," cholesterol.

Results of the Australian study are published in the Aug. 2 issue of Circulation.

Type 2 diabetes is a major risk factor for the development of cardiovascular disease, and significantly increases the likelihood of having a heart attack, according to background information in the study. Dyslipidemia (which means high LDL levels and low HDL levels) is common for people with type 2 diabetes.

The drug torcetrapib is from a class of medications called CETP inhibitors. These drugs help raise levels of HDL cholesterol.

The ILLUMINATE trial included 6,661 people
'/>"/>

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. Controversial TOFT theory of cancer versus SMT model: Authors do battle in BioEssays
2. Recommendations issued on controversial Ashley procedure for disabled children
3. K-State receives patent for noncontroversial source of stem cells
4. Review Panel Leaves Controversial Lyme Disease Guidelines Unchanged
5. Controversial urological issues top EAUs Anniversary Congress in Barcelona
6. Project Prevention Brings Controversial Sterilization Program to Honolulu
7. Scientists Discover Ultra-Bad Cholesterol
8. Experts Say Cholesterol Screenings Should Start in Childhood
9. Selenium Supplements Might Give Modest Benefit Against Cholesterol
10. Bad cholesterol not as bad as people think, shows Texas A&M study
11. Experts at Experimental Biology examine dietary cholesterol, egg intake and heart disease risk
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Controversial Cholesterol Drug Might Lower Blood Sugar Levels in Diabetics
(Date:9/30/2014)... 2014 All on Four dental ... persons who have received dental implants to vigilant in ... post. , The post, which can be found at ... if they don’t brush and floss diligently, they could ... their natural teeth: the bone will deteriorate and the ...
(Date:9/30/2014)... 2014 Youth Town’s annual BBQ/Music Festival ... to 2 p.m. at the Youth Town campus (3641 ... sponsors this family-oriented festival, which will offer music, food ... feature a car show, arts and crafts fair, music, ... games. Also, Lightning McQueen and Mater from the hit ...
(Date:9/30/2014)... 2014 “Biology and botany are ... Brickner, “and it’s about naming rights.” , In ... new on the Bryan William Brickner Blog, the ... Institutes of Health (PubMed). The post highlights five ... REM transitions, aging with THC, the wake-inducing effects ...
(Date:9/30/2014)... CA (PRWEB) September 30, 2014 Top10inaction.com, ... main focus on ranking and reviewing all essential categories ... has officially announced the best liquid foundation at ... Serum Foundation is named as the best foundation of ... drugstore as well as high end brands, hence customers ...
(Date:9/30/2014)... East Longmeadow, Massachusetts (PRWEB) September 30, 2014 ... Excellence’, the Wingate of East Longmeadow facility has ... new Ventilator Program that combines advanced ... staff. This program is one of the only ... this type of care. The primary focus ...
Breaking Medicine News(10 mins):Health News:All on Four Dental Implants Dentist Writes Blog on Preventing Gum Disease 2Health News:All on Four Dental Implants Dentist Writes Blog on Preventing Gum Disease 3Health News:Homeostasis: Publius’ Sleep Political Cannabinoid Science ~ New on the Bryan William Brickner Blog 2Health News:Yves Saint Laurent is Named As Best Liquid Foundation 2014 2Health News:Wingate Healthcare Announces New Ventilator Care Program at East Longmeadow Facility 2Health News:Wingate Healthcare Announces New Ventilator Care Program at East Longmeadow Facility 3
... mobile computing and medication carts unveils TX11: a mobile computing cart ... ... OH (PRWEB) November 11, 2008 -- The Columbus, OH based medical ... newest in their line of mobile computing carts : the ...
... MOUNTAIN VIEW, Calif., Nov. 11 The 2008 ... Product,Innovation of the Year Award is presented to ... suppressant ingredient -,Slimaluma - for the global weight ... action, superior quality and safety,standards of Slimaluma have ...
... 10 Ready or not, the holiday season,is here. ... turkey and pies, merry-making eggnog and potato latkes,and then ... come Super Bowl,buffalo wings and Valentine,s Day chocolates to ... non-stop holiday cooking and,feasting., Enter Helene Phillips, the ...
... Nov. 10 TeamHealth Inc.,s parent,company, Team Finance ... quarter ended September 30, 2008., The Company ... services business line and substantially completed the disposal,of ... 2007. In accordance with,relevant accounting guidance, the results ...
... Of $9 million appropriated by,the Texas legislature to ... automated external defibrillators (AEDs), $3.5 million remains,unclaimed. Texas ... purchase under,the reimbursement program until the November 14, ... by lay people with CPR training,to resuscitate victims ...
... Increased risk of stroke a major issue in analysis of ... An analysis of 33 studies on drugs known as beta ... surgical procedure other than heart surgery. In fact, using beta ... stroke, the scientists say. , The researchers who conducted the ...
Cached Medicine News:Health News:Mobile Computing Carts Leader to Release New Clinical Computer Cart 2Health News:Gencor Pacific Group Picks Up Frost & Sullivan Global Appetite Suppressant and Satiety Ingredients Product Innovation of the Year Award 2Health News:Gencor Pacific Group Picks Up Frost & Sullivan Global Appetite Suppressant and Satiety Ingredients Product Innovation of the Year Award 3Health News:Tips for Maintaining Your Physique While Enjoying Your Favorite Treats 2Health News:Tips for Maintaining Your Physique While Enjoying Your Favorite Treats 3Health News:Team Finance LLC Announces Third Quarter 2008 Results 2Health News:Team Finance LLC Announces Third Quarter 2008 Results 3Health News:Team Finance LLC Announces Third Quarter 2008 Results 4Health News:Team Finance LLC Announces Third Quarter 2008 Results 5Health News:Team Finance LLC Announces Third Quarter 2008 Results 6Health News:Team Finance LLC Announces Third Quarter 2008 Results 7Health News:Team Finance LLC Announces Third Quarter 2008 Results 8Health News:Team Finance LLC Announces Third Quarter 2008 Results 9Health News:$3.5 Million in Reimbursements for Purchases of Automated External Defibrillators (AEDs) for Texas Schools Still Unclaimed With Deadline Approaching 2Health News:Beta Blocker Use Questioned in Non-Heart Surgery 2Health News:Beta Blocker Use Questioned in Non-Heart Surgery 3
(Date:9/30/2014)... 2014  Come fall, many children, teenagers, and even ... want to be for Halloween. And, a number of ... contact lenses bought without a prescription. Halloween, ... purchase and wear contact lenses without a prescription. According ... consumer survey, 17 percent of Americans have worn ...
(Date:9/30/2014)... Sept. 30, 2014 CytRx Corporation (NASDAQ: ... development company specializing in oncology, today announced the ... evaluating aldoxorubicin compared to topotecan in subjects with ... relapsed or were refractory to prior chemotherapy. Aldoxorubicin ... agent, doxorubicin. CytRx has received Orphan Drug Designation ...
(Date:9/29/2014)... and DUBLIN , Sept. ... or the "Company"), a biotechnology company pioneering the manufacturing ... of innovative therapies for cancer, HIV/AIDS, opportunistic infections and ... its shareholders from CEO Noreen Griffin The letter follows: ... (the "Company" or "TNIB") received a number of calls ...
Breaking Medicine Technology:The Spooky Truth: What You Need To Know About Contact Lens Hygiene 2The Spooky Truth: What You Need To Know About Contact Lens Hygiene 3CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 2CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 3CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 4CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 5TNI BioTech, Inc. Corporation's CEO Issues Letter to Shareholders Discussing Cytocom Dividend 2TNI BioTech, Inc. Corporation's CEO Issues Letter to Shareholders Discussing Cytocom Dividend 3TNI BioTech, Inc. Corporation's CEO Issues Letter to Shareholders Discussing Cytocom Dividend 4TNI BioTech, Inc. Corporation's CEO Issues Letter to Shareholders Discussing Cytocom Dividend 5TNI BioTech, Inc. Corporation's CEO Issues Letter to Shareholders Discussing Cytocom Dividend 6TNI BioTech, Inc. Corporation's CEO Issues Letter to Shareholders Discussing Cytocom Dividend 7TNI BioTech, Inc. Corporation's CEO Issues Letter to Shareholders Discussing Cytocom Dividend 8
... 15 Tolerx, Inc., a,biopharmaceutical company engaged in ... treatment of immune-mediated diseases, announced today,the successful completion ... a novel,humanized anti-CD4 monoclonal antibody (MAb), in subjects ... study was designed to,assess the safety, tolerability, and ...
... System Runs ,Heart Model of the Future, ... To Insight, SUNNYVALE, Calif., Jan. 15 In the quest ... Montreal (UdM) have run the largest mathematical simulation of a heart,ever ... system from SGI (Nasdaq: SGIC ). The new UdM model ...
Cached Medicine Technology:Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus 2Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus 3Universite de Montreal Researchers Simulate World's Largest Heart Model Using SGI Technology 2Universite de Montreal Researchers Simulate World's Largest Heart Model Using SGI Technology 3Universite de Montreal Researchers Simulate World's Largest Heart Model Using SGI Technology 4
0.25 mm diameter textured tip with protective guard....
... for perfect focus where it's needed - ... along with Keeler's wide angle light beam ... patient's pupil size, you will see the ... technology provides a longer life battery and ...
... for perfect focus where it's needed - ... along with Keeler's wide angle light beam ... patient's pupil size, you will see the ... technology provides a longer life battery and ...
... individually adjusted for perfect focus where it's ... paper. This, along with Keeler's wide angle ... whatever the patient's pupil size, you will ... view. Lithium-ion technology provides a longer life ...
Medicine Products: